CompletedNot Applicable

Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

China129 participantsStarted 2022-06-30

Plain-language summary

This study aims to assess the one-year effectiveness and safety of LAN among patients with acromegaly in China in routine clinical practice. In addition, the study is designed to understand the real-world treatment patterns and outcomes of LAN among Chinese patients with acromegaly.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants who are able to comply with the protocol * Participants with serum IGF-1 level above the ULN for age and sex, and serum fasting GH level above 2.5 μg/L * Participants with acromegaly who are naïve to LAN treatment and about to initiate LAN Exclusion Criteria: * Participants who are currently participating in any investigational study or clinical trial of acromegaly * Pregnant participants * Participants with hypersensitivity to somatostatin or related peptides or to any of the excipients

What they're measuring

Percentage of participants achieving full biochemical control

Timeframe: At 12 months

Trial details

NCT IDNCT05431803

SponsorIpsen

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-12-13

View on ClinicalTrials.gov More Acromegaly trials